This is a story about the journey of commercialization for BMS’ first cell therapies approved for the treatment of blood cancer.
Jason ‘Jake’ Treese, played a critical role in the development, approval and commercialization of Abecma and Breyanzi; two cell therapies which have now treated 4,700 patients in clinical and commercial settings – patients that are often on their last line of treatment, and last hope of a successful treatment.
We discuss leading the quality function in CAR-T cell therapy, the challenges faced in gaining approval for these therapies, the background of CAR-T cell therapy, the importance of building a strong team, the setbacks encountered during the approval process, and the motivation and inspiration behind the work.
- Understanding CAR-T Cell Therapy
- Leading the Quality Function in CAR-T Cell Therapy
- Building the Team and Planning for Success
- Challenges and Setbacks in the Approval Process
- Maintaining Motivation and Mission
- The Approval and Reflections
- Advice for Quality Leaders in Cell Therapy
- Considerations for the Industry
- Reflections on the Impact of Cell Therapy
It’s an incredible, emotional, and highly insightful story. For anyone that is leading an organisation through clinical development, particularly within cell therapy, this is a must listen!
